News

Latest

BioSyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies.

2021-10-20

Singapore-based biotech firm Biosyngen has set its sights on developing these cell therapies to benefit an even larger group of cancer patients. PHOTO: BIOSYNGEN

MENU